Version 1
: Received: 21 November 2023 / Approved: 23 November 2023 / Online: 23 November 2023 (04:26:39 CET)
How to cite:
Vater, M.; Garrett, A.; Collier, K.; Rose, P.G.; Tinoco, G.; Strahan, A.; Stover, D.G.; Mahdi, H. Association of Circulating Tumor DNA Fraction Analysis with Clinical and Pathologic Characteristics in Endometrial and Ovarian Cancer. Preprints2023, 2023111471. https://doi.org/10.20944/preprints202311.1471.v1
Vater, M.; Garrett, A.; Collier, K.; Rose, P.G.; Tinoco, G.; Strahan, A.; Stover, D.G.; Mahdi, H. Association of Circulating Tumor DNA Fraction Analysis with Clinical and Pathologic Characteristics in Endometrial and Ovarian Cancer. Preprints 2023, 2023111471. https://doi.org/10.20944/preprints202311.1471.v1
Vater, M.; Garrett, A.; Collier, K.; Rose, P.G.; Tinoco, G.; Strahan, A.; Stover, D.G.; Mahdi, H. Association of Circulating Tumor DNA Fraction Analysis with Clinical and Pathologic Characteristics in Endometrial and Ovarian Cancer. Preprints2023, 2023111471. https://doi.org/10.20944/preprints202311.1471.v1
APA Style
Vater, M., Garrett, A., Collier, K., Rose, P.G., Tinoco, G., Strahan, A., Stover, D.G., & Mahdi, H. (2023). Association of Circulating Tumor DNA Fraction Analysis with Clinical and Pathologic Characteristics in Endometrial and Ovarian Cancer. Preprints. https://doi.org/10.20944/preprints202311.1471.v1
Chicago/Turabian Style
Vater, M., Daniel G Stover and Haider Mahdi. 2023 "Association of Circulating Tumor DNA Fraction Analysis with Clinical and Pathologic Characteristics in Endometrial and Ovarian Cancer" Preprints. https://doi.org/10.20944/preprints202311.1471.v1
Abstract
There is no routine approach to identify patients with gynecologic malignancies at high risk for chemotherapy-resistance. Circulating tumor DNA (ctDNA) tumor fraction (TFx) represents a minimally-invasive approach to tumor profiling, with as yet limited data on utility in gynecologic malignancies. The objective was to investigate the use of ctDNA TFx in a cohort of patients with ovarian and endometrial cancer. Plasma samples from patients with biopsy-proven ovarian or endometrial cancer collected between 4/2018 and 4/2020 were subjected to shallow whole genome sequencing with determination of TFx via ichorCNA package. The association of TFx to continuous and categorical baseline clinicopathologic factors and progression-free survival was assessed. 210 plasma samples from 78 patients with gynecologic cancers were analyzed. Mean TFx for ovarian cancer was 5.5% and endometrial cancer 2.4% and there was no significant difference in TFx among histology either for endometrial or ovarian cancers. Grade was associated with significant difference in ‘sentinel’ TFx among ovarian cancers but not endometrial cancers. ctDNA TFx dynamics over time demonstrated rapid clearance of ctDNA in most patients with ovarian cancer, while endometrial cancer had consistently low TFx. ctDNA TFx is feasible in ovarian and endometrial cancers and may be a valuable important tool for prognostication.
Keywords
ovarian cancer; circulating tumor dna; biomarker
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
